Medical Condition News

RSS

Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology, to be held on December 4-7 in Orlando, FL, the company announced today. Kenna Anderes, VP Cancer Biology at Cylene, will discuss research on targeting CK2, a protein kinase that is essential for the progression of multiple myeloma but that has not been previously exploited as an anticancer target.

7 Dec 2010

FAI releases comprehensive food allergy guidelines

The Food Allergy Initiative (FAI) today announced its endorsement of comprehensive food allergy guidelines, released by an Expert Panel sponsored by the National Institute of Allergy and Immunology (NIAID), a division of the National Institutes of Health (NIH). FAI, the largest private source of funding for food allergy research in the U.S., will underwrite the publication of the long-awaited Guidelines as a special supplement to the December 2010 issue of the prestigious Journal of Allergy and Clinical Immunology.

7 Dec 2010

Global phase III study to provide novel extended release of topiramate

Data presented yesterday showed that USL255, a novel extended-release (ER) formulation of topiramate, was associated with less fluctuation in topiramate plasma levels than immediate-release (IR) topiramate in healthy volunteers.

7 Dec 2010

Pfizer CEO unexpectedly retires

As the chairman of the trade group Pharmaceutical Research and Manufacturers of America, Kindler was instrumental in lining up drugmaker support for this year's health care overhaul in a deal that ultimately will bring those companies more customers and sales. The industry had helped defeat the Clinton adminstration's attempt to reform health care in 1994

7 Dec 2010

Data analysis reveals significant risk factors for sudden unexpected death in epilepsy

Sudden unexpected death in epilepsy (SUDEP) is the most common condition-related cause of death in chronic epilepsy. Case-control studies using living people with epilepsy as controls have aimed at identifying factors that distinguish the epilepsy patient at risk of SUDEP, but there are disagreements between studies and a lack of precision in the risk estimates attributed, in part, to the small number of cases in each study.

7 Dec 2010

Rexahn Pharmaceuticals announces US patent for cognition enhancement

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,842,683 entitled, "Neurotherapeutic Compositions and Methods."

7 Dec 2010

Boston Scientific's Close the Gap campaign to raise awareness of heart disease risk factors

Boston Scientific today announced that its Close the Gap campaign is partnering with the Black Coaches and Administrators and college basketball's "The Showcase" to raise awareness of heart disease risk factors for women and minorities.

7 Dec 2010

No overall cancer risk in people who donate stem cells

American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

7 Dec 2010

Mayo Clinic scientists say JAK inhibitors may help treat patients with myelofibrosis

Two janus kinase (JAK) inhibitors are substantially improving treatment of myelofibrosis in patients, say Mayo Clinic researchers who are presenting results of several clinical trials at the 52nd annual meeting of the American Society of Hematology (ASH) Dec. 4 in Orlando.

7 Dec 2010

Microsulis Medical announces first U.S. patient treated with Accu2i percutaneous microwave tissue ablation system

Microsulis Medical Limited, the leading company in microwave technology for medical devices, today announced that the first U.S. patient was treated with the company's Accu2i percutaneous microwave tissue ablation (pMTA) system. The Accu2i pMTA system, which is now in worldwide distribution, is indicated for the coagulation of soft tissue during surgical procedures and recently received U.S. Food and Drug Administration (FDA) clearance.

7 Dec 2010

Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH

Acetylon Pharmaceuticals today announced the publication of favorable results of preclinical safety and efficacy testing of its oral selective HDAC6 inhibitor drug candidate, ACY-1215, in multiple myeloma.

7 Dec 2010

Scientists have learned to mask bitterness of ginseng to improve consumers health

University of Illinois scientists have learned to mask the bitterness of ginseng, a common ingredient of energy drinks.

7 Dec 2010

Positive interim data from Phase I/II trial of CYT387 in myelofibrosis presented at ASH Annual Meeting

YM BioSciences Inc. today announced positive interim data from the first 60 patients enrolled in the Phase I/II trial for its JAK1/JAK2 inhibitor, CYT387, in myelofibrosis. The results were reported today in an oral presentation at the 52nd American Society of Hematology Annual Meeting being held in Orlando, Florida.

7 Dec 2010

rVWF safe in patients with type 3 and severe type 1 von Willebrand disease, suggests interim study data

Recombinant von Willebrand factor (rVWF) may be safe and well tolerated in patients with type 3 and severe type 1 von Willebrand disease, according to interim data from a Phase 1 multicenter, international clinical study presented today at the 52nd Annual Meeting of the American Society of Hematology.

From Baxter International Inc. 7 Dec 2010

Study: Mixing exenatide with insulin provides better blood sugar control in type 2 diabetes patients

A new study finds that combining the newer diabetes drug exenatide with insulin provides better blood sugar control in patients with type 2 diabetes than insulin alone and helps promote weight loss.

7 Dec 2010

New drug appears to help patients with chronic myeloid leukemia

A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start, researchers reported at the 52nd Annual Meeting of the American Society of Hematology.

7 Dec 2010

Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia

Ascenta Therapeutics, Inc. and The Leukemia & Lymphoma Society (LLS) today entered into an agreement whereby the LLS will support clinical development of Ascenta's oral small molecule inhibitor of IAPs (inhibitor of apoptosis proteins), AT-406, for patients with acute myeloid leukemia (AML).

7 Dec 2010

High blood pressure may be caused by racial and geographic differences

High blood pressure may help to explain why deaths from heart disease and stroke vary according to geography, race and sex, researchers reported in Hypertension: Journal of the American Heart Association.

7 Dec 2010

Researchers examine relationship between childhood obesity, physical activity

Scientists may have discovered a new trend in childhood obesity, according to research published this month in Medicine & Science in Sports & Exercise, the official journal of the American College of Sports Medicine. In comparing physical activity levels among American children, researchers discovered that the most overweight and obese ethnic groups are also some of the most active.

7 Dec 2010

Thesis reveals stressed young women develop more neck pain than male counterparts

Neck pain is more common in women than men, irrespective of occupation or age. Stressed young women develop more neck pain than their male counterparts. Women also perceive everyday life to be more stressful, reveals a thesis from the University of Gothenburg, Sweden.

7 Dec 2010

Medical Condition News

Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

FAI releases comprehensive food allergy guidelines

Global phase III study to provide novel extended release of topiramate

Pfizer CEO unexpectedly retires

Data analysis reveals significant risk factors for sudden unexpected death in epilepsy

Rexahn Pharmaceuticals announces US patent for cognition enhancement

Boston Scientific's Close the Gap campaign to raise awareness of heart disease risk factors

No overall cancer risk in people who donate stem cells

Mayo Clinic scientists say JAK inhibitors may help treat patients with myelofibrosis

Microsulis Medical announces first U.S. patient treated with Accu2i percutaneous microwave tissue ablation system

Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH

Scientists have learned to mask bitterness of ginseng to improve consumers health

Positive interim data from Phase I/II trial of CYT387 in myelofibrosis presented at ASH Annual Meeting

rVWF safe in patients with type 3 and severe type 1 von Willebrand disease, suggests interim study data

Study: Mixing exenatide with insulin provides better blood sugar control in type 2 diabetes patients

New drug appears to help patients with chronic myeloid leukemia

Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia

High blood pressure may be caused by racial and geographic differences

Researchers examine relationship between childhood obesity, physical activity

Thesis reveals stressed young women develop more neck pain than male counterparts

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Latest News